John Alexander

9PUBLICATIONS
70CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 22, 2026
The anion channel GPR89 is a tumor-specific dependency in breast cancer.

|Apr 10, 2024
Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer.

John Alexander, Koen Schipper, Sarah Nash

|Oct 06, 2023
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.

Arany Soosainathan, Marjan Iravani, Rania El-Botty

|Oct 23, 2022
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance.

Marta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev

|Nov 09, 2021
Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency.

Ilirjana Bajrami, Callum Walker, Dragomir B Krastev

|Jun 11, 2021
Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis.

Ute Jungwirth, Antoinette van Weverwijk, Rachel J Evans

Pageof 2

Frequent Collaborators

7 joint publications

Syed Haider

5 joint publications

Christopher J Lord

4 joint publications

Stephen Pettitt

3 joint publications

Clare M Isacke